Topics

KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019

07:30 EDT 30 Apr 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
– Novel Oral Plasma Kallikrein Inhibitors KV998052 and KV998054 Prevent and Reverse VEGF-Induced Retinal Edema in Mice – KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on th...

Other Sources for this Article

KalVista Pharmaceuticals, Inc.
Leah Monteiro
Director, Corporate Communications & Investor Relations
857-999-0808
leah.monteiro@kalvista.com

NEXT ARTICLE

More From BioPortfolio on "KalVista Pharmaceuticals Presents Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2019"

Quick Search

Relevant Topics

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...